On paper, things should be looking up for Japan’s pharmaceutical wholesalers. Industry expectations are mounting that the average gap between NHI and market prices will narrow further in FY2026 from the previous year’s record low of 4.8%.A shrinking gap should…
HOME > TOP STORIES
TOP STORIES
-
REGULATORY MOF Panel Submits Budget Proposal, Urges Wider CEA Use and More Frequent Re-Pricing
December 3, 2025
-
BUSINESS Lundbeck Japan Plans to Double Workforce by 2028 as It Eyes 3 Drug Approvals
December 2, 2025
-
REGULATORY Japan Allocates 100 Billion-Plus Yen for Drug Innovation, Generic Funds: FY2025 Extra Budget
December 1, 2025
-
BUSINESS Insmed Japan to Double Sales Force with Brensocatib Launch on the Horizon
November 28, 2025
-
REGULATORY US Unveils Up to 85% Price Cuts for IRA Round-2; Astellas’ Xtandi on the List
November 27, 2025
-
BUSINESS Novartis Eyes Broader Radioligand Therapy Footprint in Japan as Pluvicto Debuts
November 26, 2025
-
BUSINESS Eisai to Unify Global HR Framework by 2029 to Bolster Leqembi Growth
November 25, 2025
-
BUSINESS Marubeni Pharma Targets Doubling Profits by FY2035 with 2 New Deals Each Year
November 25, 2025
-
REGULATORY LDP, Ishin Start Framing Copay Models for OTC-Like Drugs: Bilateral Talks
November 25, 2025
-
REGULATORY Japan Finalizes Economic Package Positioning Pharma as “Core Industry”
November 25, 2025
-
REGULATORY Patient Groups Push Back against Delisting OTC-Like Drugs; Panel Leans Toward Higher Copays
November 21, 2025
-
REGULATORY Japan Approves Label Expansions for Braftovi, Augtyro, Uplizna, and More
November 21, 2025
-
REGULATORY Providers Push to Expand 2% Buffer Zone in Drug Price Revisions as Costs Rise
November 20, 2025
-
REGULATORY Japan Moves to Advance “G1” Price Cuts by 5 Years under Proposed LLP Overhaul
November 20, 2025
-
BUSINESS Boehringer Sees Oncology as Pillar of Japan Business, Starting with Hernexeos
November 20, 2025
-
ORGANIZATION PhRMA Chief Warns Japan Is Losing Its Appeal, Urges End to On-Patent Price Cuts
November 19, 2025
-
BUSINESS Japan’s Big 4 Wholesalers Lower Operating Margin as COVID-19 Windfall Recedes
November 18, 2025
-
REGULATORY Japan Launches Pilot Expert Committee System for Patent Linkage Reviews, Aims to Reduce IP Feuds
November 17, 2025
-
COMMENTARY MOF Autumn Proposals Signal a Shift from Drug Pricing to Cost-Sharing Reform
November 17, 2025
-
REGULATORY Chuikyo Split over Higher Copays under LLP Scheme; Payer Push Meets Provider Caution
November 17, 2025
ページ
Japan is set to add 16 new drugs to its NHI reimbursement price list on November 13, including a subcutaneous…
Japan will trim the NHI price of Eli Lilly Japan’s Alzheimer’s treatment Kisunla (donanemab) by 3.93% under the cost-effectiveness assessment…
Tariffs have been a defining feature of US trade policy under President Donald Trump’s second administration. Since Trump unveiled his “reciprocal” tariff policy in April 2025, the landscape has shifted repeatedly.In February 2026, the US Supreme Court invalidated tariffs imposed…
As Japan’s budget season draws near, the Ministry of Finance (MOF) has renewed its push for a full-scale “off-year” drug…
Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…